A pandemic is not inevitable, scientists say. But the outbreak has passed worrisome milestones in recent weeks, including ...

Moderna is set to receive $590m in funding from the HHS to expedite the development of mRNA-based pandemic influenza vaccines ...

The government wants Moderna to push forward with various bird flu vaccines as well as mRNA shots for other influenza strains ...

(“Cocrystal” or the “Company”) announces plans to extend enrollment in the Phase 2a human challenge study with its investigational, broad-spectrum, oral influenza PB2 inhibitor CDI-42344 ...

In 2023, Moderna initiated a study on a “pandemic influenza vaccine” to protect against H5 and ... Moderna plans to advance ...

The U.S. Department of Health and Human Services (HHS) is awarding the pharmaceutical company Moderna $590 million to ...

Extension of enrollment in the Phase 2a study allows for continued evaluation of CC-42344, potentially leading to more robust data on its efficacy against influenza A. CC-42344 has demonstrated ...

Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...

Cocrystal Pharma has announced its intent to extend enrolment for its Phase IIa human challenge trial of the oral influenza polymerase basic 2 (PB2) inhibitor, CC-42344, following unpredictable ...

Moderna gets a $590 million federal boost to continue work on development of a vaccine to protect against bird flu.

The Department of Health and Human Services (HHS) will award roughly $590 million to Moderna to accelerate the development of ...